Michal Levy

Dr. Michal Levy


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2024 in Prenatal Diagnosis
Verified
Journal Article
Open access
MLMichal Levy
Michal Levy
SLShira Lifshitz
Shira Lifshitz
MGMirela Goldenberg‐Fumanov
Mirela Goldenberg‐Fumanov
LBLily Bazak
Lily Bazak
RGRayna Joy Goldstein
Rayna Joy Goldstein
MSMordechai Shohat
Mordechai Shohat
Objective: This study aimed to assess the detection rate of clinically significant results of prenatal exome sequencing (pES) in low‐risk pregnancies and apparently normal fetuses in non‐consanguineous couples.Methods: A retrospective analysis of pES conducted at a single center from January 2020 to September 2023 was performed. Genetic counseling was provided, and detailed medical histories were obtained. High‐risk pregnancies were excluded due to major ultrasound anomalies, sonographic soft markers, abnormal maternal biochemical screening, or family history suggestive of monogenic diseases as well as cases with pathogenic and likely pathogenic (P/LP) chromosomal microarray results. Exome analysis focused on ∼2100 genes associated with Mendelian genetic disorders. Variant analysis and classification followed the American College of Medical Genetics and Genomics (ACMG) guidelines.Results: Among 1825 pES conducted, 1020 low‐risk cases revealed 28 fetuses (2.7%) with potentially clinically significant variants indicating known monogenic diseases, primarily de novo dominant variants (64%). Among these 28 cases, 9 fetuses (0.9%) had the potential for severe phenotypes, including shortened lifespan and intellectual disability, and another 12 had the potential for milder phenotypes. Seven cases were reported with variants of uncertain significance (VUS) that, according to the ACMG criteria, leaned toward LP, constituting 0.7% of the entire cohort. Termination of pregnancy was elected in 13 out of 1020 cases (1.2%) in the cohort, including 7/9 in the severe phenotypes group, 2/12 in the milder phenotype group, and 4/7 in the VUS group.Conclusion: The 2.7% detection rate highlights the significant contribution of pES in low‐risk pregnancies. However, it necessitates rigorous analysis, and comprehensive genetic counseling before and after testing.

27 January 2020 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MLMichal Levy
Michal Levy
MKMichal Kovo
Michal Kovo
HMHadas Miremberg
Hadas Miremberg
NANoa Anchel
Noa Anchel
HHHadas Ganer Herman
Hadas Ganer Herman
EWEran Weiner
Eran Weiner

1 November 2021 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
JBJacob Bar
Jacob Bar
EWEran Weiner
Eran Weiner
MLMichal Levy
Michal Levy
YGYinon Gilboa
Yinon Gilboa

20 March 2020 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
MLMichal Levy
Michal Levy
MKMichal Kovo
Michal Kovo
GBGiulia Barda
Giulia Barda
OGOhad Gluck
Ohad Gluck
LKLiron Koren
Liron Koren
EWEran Weiner
Eran Weiner

20 January 2020 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
MLMichal Levy
Michal Levy
MKMichal Kovo
Michal Kovo
YIYakira Izaik
Yakira Izaik
ICIsca Luwisch Cohen
Isca Luwisch Cohen
LSLetizia Schreiber
Letizia Schreiber
EWEran Weiner
Eran Weiner

1 October 2018 in Reproductive Sciences
Verified
Journal Article
Closed access
MLMichal Levy
Michal Levy
YMYossi Mizrachi
Yossi Mizrachi
SLSophia Leytes
Sophia Leytes
EWEran Weiner
Eran Weiner
JBJacob Bar
Jacob Bar
Michal KovoMichal Kovo
Michal Kovo